Patrick Kristin 4

What Happened

• Patrick Kristin, a director of Niagen Bioscience, was granted a derivative award representing 31,746 shares on June 24, 2026. The reported acquisition price is $0.00, indicating a non-cash grant (derivative security/option). The filing lists the instrument as a derivative and shows a total immediate value of $0.

Key Details

• Transaction date: 2026-06-24
• Transaction type/code: Grant / Award (A) — derivative security
• Shares/units granted: 31,746 (acquired at $0.00)
• Vesting: Option vests 100% on June 24, 2027 (Footnote F1)
• Shares owned after transaction: Not reported in the filing
• Filing date: 2026-06-26 — appears filed within the typical Form 4 reporting timeframe (timely)

Context

• This was an award of a derivative instrument (most likely stock options) that vests in one year; it does not represent an immediate cash purchase or sale. Such grants are common as director compensation and do not by themselves indicate buying or selling pressure. There is no indication the award was exercised or sold.